SeaStar Medical Holding Corp(ICU)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.2M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ICU Stock Analysis & AI Quality Score
AI stock analysis and institutional research for SeaStar Medical Holding Corp (ICU), a Healthcare sector company. ICU is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.2m in revenue. Based on the latest XBRL financial filings (Q1 2026), SeaStar Medical Holding Corp reports quarterly revenue of $495.0K, net income of $-3.5M, free cash flow of $-2.8M. Top institutional holders of ICU by reported 13-F value include GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, JANE STREET GROUP,, based on the most recent SEC filings. ICU trades on the Nasdaq exchange and files with the SEC under CIK 1831868. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ICU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SeaStar Medical Holding Corp directly from SEC EDGAR.
Revenue
Q1 2026
$495.0K
Net Income
Q1 2026
$-3.5M
Free Cash Flow
Q1 2026
$-2.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+814.1% YoYNet Income
+51.1% YoYOperating Income
+31.8% YoYEPS (Diluted)
Total Assets
+204.0% YoYTotal Debt
Op. Cash Flow
+15.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $1.2M +814.1% | $135.0K | $0.00 | — | — |
| Net Income | $-12.2M +51.1% | $-24.8M +5.3% | $-26.2M -115.2% | $-12.2M | — |
| Operating Income | $-12.2M +31.8% | $-17.8M -25.6% | $-14.2M -22.4% | $-11.6M | — |
| EPS (Diluted) | — | $-3.31 +78.1% | $-15.13 -1944.6% | $-0.74 | — |
| Total Assets | $14.2M +204.0% | $4.7M +32.6% | $3.5M +15.6% | $3.0M +1028.5% | $269.2K |
| Total Debt | — | $574.0K -88.4% | $4.9M -44.1% | $8.8M | — |
| Operating Cash Flow | $-13.6M +15.0% | $-16.0M -55.6% | $-10.3M -32.0% | $-7.8M | — |
AI Insight: ICU Ratio Trends
SeaStar Medical remains deeply unprofitable with ROE deteriorating to -192.5% in Q1 2026, signaling persistent losses and shareholder value destruction.
• ROA improved from -95.5% in Q2 2025 to -82.0% in Q4 2025, but reversed sharply in Q1 2026 with ROE collapsing to -192.5%.
• All profitability metrics remain negative; no operating margin, NPM, or ROIC data available indicates the company is not yet generating positive earnings.
⚠ ROE deteriorated 80pp quarter-over-quarter from Q4 2025 (-111.5%) to Q1 2026 (-192.5%) — largest single-quarter decline in available data.
⚠ Consistent multi-quarter losses with no margin expansion or profitability inflection visible — critical to monitor path to breakeven.
Get alerted when ICU's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for SeaStar Medical Holding Corp including:
Top Institutional Holders of ICU
GEODE CAPITAL MANAGEMENT, LLC
$207.0K55,642 shVANGUARD CAPITAL MANAGEMENT LLC
$107.1K28,791 shJANE STREET GROUP, LLC
$104.0K27,960 shVANGUARD FIDUCIARY TRUST CO
$50.9K13,692 shPNC FINANCIAL SERVICES GROUP, INC.
$6.5K1,748 shTower Research Capital LLC (TRC)
$5.2K1,395 shBlackRock, Inc.
$3.4K913 shUBS Group AG
$3.0K793 shOSAIC HOLDINGS, INC.
$854.00230 shVanguard Global Advisers, LLC
$614.00165 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $207.0K | 55,642 |
| VANGUARD CAPITAL MANAGEMENT LLC | $107.1K | 28,791 |
| JANE STREET GROUP, LLC | $104.0K | 27,960 |
| VANGUARD FIDUCIARY TRUST CO | $50.9K | 13,692 |
| PNC FINANCIAL SERVICES GROUP, INC. | $6.5K | 1,748 |
| Tower Research Capital LLC (TRC) | $5.2K | 1,395 |
| BlackRock, Inc. | $3.4K | 913 |
| UBS Group AG | $3.0K | 793 |
| OSAIC HOLDINGS, INC. | $854.00 | 230 |
| Vanguard Global Advisers, LLC | $614.00 | 165 |
More Healthcare Companies
View all Healthcare →Put ICU on your watchlist
Track score changes the day SeaStar Medical Holding Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ICU a good stock to buy?
13F Pro's AI-powered analysis of SeaStar Medical Holding Corp (ICU) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ICU are available on the ICU stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ICU?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ICU. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SeaStar Medical Holding Corp's investment landscape.